Navigation Links
ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
Date:3/3/2009

7.

Marketing and selling expenses have increased by 9% to EUR 1.1 million in 2008, compared to EUR 1.0 million in 2007. This rise is driven by increased marketing effort in the diagnostic field.

General and administrative costs increased by 30% to EUR 4.6 million in 2008, compared to EUR 3.5 million in 2007. This increase is primarily due to significant expenses incurred to defend our IP portfolio.

Operating expenses increased by 18% to EUR 15.6 million in 2008 compared to EUR 13.2 million in 2007. In 2008, 63% of these expenses were allocated to R&D compared to 65% in 2007.

Consequently, the company posted an operating loss of EUR 11.4 million in 2008, compared to EUR 7.8 million in 2007.

The end of some leasing agreements explains the decrease in interest expenses between 2007 and 2008 from EUR 0.8 million to EUR 0.5 million. Meanwhile, a decrease on our cash and cash equivalent balances combined with the decrease of interest rates over 2008 leads to lower financial gains in 2008 at EUR 0.9 million versus EUR 1.3 million in 2007. Nonetheless, the favorable evolution of the euro/dollars exchange rate between the two years has led to a currency rate gain of EUR 0.02 million during 2008, compared to a loss of EUR 0.7 million in 2007. As a consequence, the financial result amounts to a gain of EUR 0.38 million in 2008 compared to a loss of EUR 0.22 million in 2007.

The modification of the way research tax credits have been calculated since January 1, 2008 led to an increase of the income tax benefit from EUR 0.7 million in 2007 to EUR 2.1 million in 2008.

As a consequence, ExonHit recorded a consolidated net loss of EUR 8.9 million in 2008, compared to EUR 7.3 million in 2007.

- Balance sheet

On December 31, 2008, the cash position of the Company amounted to EUR 21.0 million, compared to EUR 31.3 million at the end of 20
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI)
2. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
3. Loic Maurel Joins Exonhit Therapeutics to Become CEO
4. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
5. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
6. ExonHit Appoints a New Management Board
7. ExonHit Therapeutics - 2007 Financial Results
8. ExonHit Builds A New Organisation
9. ExonHit and bioMerieux Amend Their Strategic Partnership
10. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
11. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 2015 According to the new Market ... Pre-formulated Media), by Application (Biobanking, Regenerative Medicine, Drug Discovery), by ... , Asia-Pacific , Rest of the ... media market was valued at $247.7 million in 2014, which ... at a CAGR of 18.2% between 2014 and 2019. ...
(Date:7/27/2015)... ... 27, 2015 , ... Visual Assay was named as a finalist for the ... technologies and services of the past year. More than 70 judges selected the finalists, ... will be announced at the 2015 R&D 100 Awards Dinner on November 13 at ...
(Date:7/24/2015)... (PRWEB) , ... July 24, 2015 , ... VetStem Biopharma, ... Center in support of stem cell therapy training and clinical opportunities. , “We are ... opportunity to veterinarians in the San Diego area. Stem cell therapy is an established ...
(Date:7/24/2015)... , July 24, 2015 Origin Agritech Limited (NASDAQ ... crop seeds in China , today announced ... fiscal year 2015 ended June 30, 2015, before the market ... will host a teleconference on August 5th, 2015, at 9:00 ... time to discuss the results. To participate in the call, ...
Breaking Biology Technology:Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3
... , KNOXVILLE, Tenn., Sept. 16 Marking ... colon cancer, EDP Biotech Corporation (EDP), ... today that its ColoMarker(TM) assay achieved 100 percent detection rate ... pre-clinical trials. ColoMarker is the first assay of its kind ...
... SAN DIEGO, Sept. 16 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: ... new class of small molecule compounds based on endogenous adrenal steroid ... Stock Market on September 15, 2009. , , ... Marketplace Rule 4450(a)(5) (the "Minimum Bid Price Rule") because its common ...
... Collaboration with Biomodels facilitates development of novel drug product , ... Inc., a biotechnology company developing oral antibodies for disease targets accessible ... a Phase I SBIR grant from the National Institute of Dental ... therapeutic for oral mucositis. , , Avaxia is ...
Cached Biology Technology:New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials 2New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials 3Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 2Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 3Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 2Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 3
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... personalized medicine for Parkinson,s disease, by investigating signs of ... cells respond to drug treatments. The study was funded ... collected skin cells from patients with genetically inherited forms ... They found that neurons derived from individuals with distinct ...
... is the way to go, if you are a primate ... orangutans, researchers have measured the energy required to navigate a ... up in the trees. Their work was presented at the ... July 2012. The findings help us to understand ...
... Laboratory of Neuro Imaging (LONI) has been responsible for ... generated by the Alzheimer,s Disease Neuroimaging Initiative (ADNI), an ... of Alzheimer,s disease. That stream of ... partners with an ambitious publicprivate effort to dig deeper ...
Cached Biology News:Patient-derived stem cells could improve drug research for Parkinson's 2Patient-derived stem cells could improve drug research for Parkinson's 3Patient-derived stem cells could improve drug research for Parkinson's 4Revolutionary project will obtain entire genome sequences in fight against Alzheimer's 2Revolutionary project will obtain entire genome sequences in fight against Alzheimer's 3
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
Biology Products: